Poland Green Lights Little Green Pharma
Poland Green Lights Little Green Pharma
Little Green Pharma (ASX:LGP) has announced that its Desert Flame high THC (20%) medicinal cannabis flower product has received Marketing Authorisation in Poland. This marks a significant milestone for the company, providing new opportunities in the rapidly growing medicinal cannabis market in Poland.
Little Green Pharma（ASX: LGP）宣佈，其Desert Flame高四氫大麻酚（20％）藥用大麻花產品已在波蘭獲得上市許可。這對公司來說是一個重要的里程碑，爲波蘭快速增長的藥用大麻市場提供了新的機會。
In Poland, Marketing Authorisations are the exclusive pathway for the supply of medicinal cannabis products. Presently, there are ten Marketing Authorisations granted for cannabis flower products with THC content in the range of 18-22%. The wholesale prices of medicinal cannabis flower in this category typically range from $7.50 to $9.50 per gram, while retail prices range between $11 and $15 per gram.
在波蘭，上市許可是供應藥用大麻產品的唯一途徑。目前，四氫大麻酚含量在18-22％之間的大麻花產品已獲得十項上市許可。此類藥用大麻花的批發價格通常在每克7.50美元至9.50美元之間，而零售價在每克11美元至15美元之間。
LGP's distribution partner in Poland, Medezin S.p. z.o.o., will be responsible for holding the Marketing Authorisation and distributing the Desert Flame product on a white-label basis during the term of their distribution agreement. Medezin is a highly experienced and large-scale pharmaceutical distributor and is a wholly owned subsidiary of Pelion SA, the largest operator in the Polish and Lithuanian healthcare sectors.
LGP在波蘭的分銷合作伙伴Medezin S.p. z.o.o. 將負責持有營銷許可，並在分銷協議期限內以白標方式分銷Desert Flame產品。Medezin是一家經驗豐富的大型藥品分銷商，是波蘭和立陶宛醫療保健領域最大的運營商Pelion SA的全資子公司。
The initial shipment of Desert Flame high THC medicinal cannabis flower from LGP to Poland is scheduled for October 2023. The company views Poland as a highly promising medicinal cannabis market, with a predicted compound annual growth rate (CAGR) of 16%. Factors contributing to this optimistic outlook include Poland's population of 38 million, an import-only supply regime, GP prescribing capability, and no restrictions on the conditions treatable with cannabis.
Desert Flame 高四氫大麻酚藥用大麻花定於2023年10月首次從LGP運往波蘭。該公司認爲波蘭是一個非常有前途的藥用大麻市場，預計複合年增長率（CAGR）爲16％。促成這種樂觀前景的因素包括波蘭的3,800萬人口、僅限進口的供應制度、全科醫生的處方能力以及對大麻可治療的疾病沒有限制。
LGP's successful acquisition of Marketing Authorisation in Poland demonstrates the company's preparedness to register additional products in Poland and other jurisdictions with similar barriers to entry.
LGP成功收購了波蘭的營銷授權，這表明該公司已準備好在波蘭和其他具有類似准入壁壘的司法管轄區註冊其他產品。
With this latest development, LGP reinforces its position as a significant global exporter of medicinal cannabis. The company's export-led sales strategy is further validated, positioning LGP to capitalize on the increasing demand for medicinal cannabis products in Europe.
憑藉這一最新進展，LGP鞏固了其作爲藥用大麻全球重要出口國的地位。該公司以出口爲導向的銷售戰略得到了進一步驗證，這使LGP能夠利用歐洲對藥用大麻產品不斷增長的需求。
The grant of Marketing Authorisation in Poland presents a notable opportunity for Little Green Pharma Ltd, expanding its presence in a promising market and enhancing its reputation as a key player in the global medicinal cannabis industry.
在波蘭獲得上市許可爲Little Green Pharma Ltd提供了一個難得的機會，它擴大了其在充滿希望的市場中的影響力，並提高了其作爲全球藥用大麻行業關鍵參與者的聲譽。
